Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome.

ABSTRACT:

Background

More effective treatments are needed for patients with postinfectious, diarrhoea-predominant, irritable bowel syndrome (IBS-D). Accordingly, we conducted a randomised, double-blind, placebo-controlled, 8-week-long trial to assess the efficacy and safety of oral glutamine therapy in patients who developed IBS-D with increased intestinal permeability following an enteric infection.

Methods

Eligible adults were randomised to glutamine (5 g/t.i.d.) or placebo for 8 weeks. The primary end point was a reduction of ≥50 points on the Irritable Bowel Syndrome Severity Scoring System (IBS-SS). Secondary endpoints included: raw IBS-SS scores, changes in daily bowel movement frequency, stool form (Bristol Stool Scale) and intestinal permeability.

Results

Fifty-four glu

SUBMITTER: Zhou Q 

PROVIDER: S-EPMC9549483 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature